Publications

Universal Switchable CAR Platform

Publications

Koedam J, Wermke M, Ehninger A, Cartellieri M, Ehninger G. Chimeric antigen receptor T-cell therapy in acute myeloid leukemia. Curr Opin Hematol. 2022, doi: 10.1097/MOH.0000000000000703.

Wermke M, Kraus S, Ehninger A et al. Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML. Blood. 2021, 137(22):3145-8. 

Meyer JE, Loff S, Dietrich J et al. Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML. Oncoimmunology. 2021, 10(1):1945804. 

Kittel-Boselli E, González Soto KE, Rodrigues Loureiro L et al. Targeting Acute Myeloid Leukemia Using the RevCAR Platform: A Programmable, Switchable and Combinatorial Strategy. Cancers (Basel). 2021, 13(19):4785. 

Loff S, Dietrich J, Meyer JE et al. Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia. Mol Ther Oncolytics. 2020, 17:408-20. 

Feldmann A, Hoffmann A, Bergmann R et al. Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy. Oncoimmunology. 2020, 9(1):1785608. 

Koristka S, Ziller-Walter P, Bergmann R et al. Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells. Cancer Immunol Immunother. 2019, 68(9):1401-15. 

Loff S, Dietrich J, Meyer JE, Riewaldt J, Spehr J, von Bonin M, Gründer C,Swayampakula M, Franke K, Feldmann A, Bachmann M, Ehninger G, Ehninger A, Cartellieri M, 2020. Rapidly Switchable Universal CAR-T cells for Treatment of CD123-positive Leukemia, Molecular Therapy:Oncolytics, doi: https://doi.org/10.1016/j.omto.2020.04.009.

Mitwasi N, Feldmann A, Arndt C, Koristka S, Berndt N, Jureczek J, Loureiro L R, Bergmann R, Máthe D, Hegedüs N, Kovács T, Zhang C, Oberoi P, Jäger E, Seliger B, Rössig C, Temme A, Eitler J, Tonn T, Schmitz M, Hassel J C, Jäger D, Wels W S, Bachmann M, 2020. “UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells. Nature Scientific Reports 10:2141, doi: 10.1038/s41598-020-59082-4

Arndt C, Feldmann A, Koristka S, Schafer M, Bergmann R, Mitwasi N, Berndt N, Bachmann D, Kegler A, Schmitz M, Puentes-Cala E, Soto J A, Ehninger G, Pietzsch J, Liolios C, Wunderlich G, Kotzerke J, Kopka K, Bachmann M, 2019. A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR. Oncoimmunology 8, 1659095.

Jureczek J, Bergmann R, Berndt N, Koristka S, Kegler A, Puentes-Cala E, Soto J A, Arndt C, Bachmann M, Feldmann A, 2019. An oligo-His-tag of a targeting module does not influence its biodistribution and the retargeting capabilities of UniCAR T cells. Sci Rep 9, 10547.

Kegler A, Koristka S, Bergmann R, Berndt N, Arndt C, Feldmann A, Hoffmann A, Bornhauser M, Schmitz M, Bachmann M P, 2019. T cells engrafted with a UniCAR 28/z outperform UniCAR BB/z-transduced T cells in the face of regulatory T cell-mediated immunosuppression. Oncoimmunology 8, e1621676.

Albert S, Koristka S, Gerbaulet A, Cartellieri M, Arndt C, Feldmann A, et al. Tonic Signaling and Its Effects on Lymphopoiesis of CAR-Armed Hematopoietic Stem and Progenitor Cells. J Immunol. 2019, 202(6):1735-1746. doi: 10.4049/jimmunol.1801004.

Loureiro LR, Feldmann A, Bergmann R, Koristka S, Berndt N, Arndt C, et al. Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells. Blood Cancer J. 2018, 8(9):81. doi: 10.1038/s41408-018-0113-4.

Koristka S, Kegler A, Bergmann R, Arndt C, Feldmann A, Albert S, et al. Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology. J Autoimmun. 2018, 90:116-131. doi: 10.1016/j.jaut.2018.02.006.

Albert S, Arndt C, Koristka S, Berndt N, Bergmann R, Feldmann A, et al. From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo. Oncotarget. 2018, 9(39):25597-25616. doi: 10.18632/oncotarget.25390.

Bachmann D, Aliperta R, Bergmann R, Feldmann A, Koristka S, Arndt C, et al. Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells. Oncotarget. 2017, 9(7):7487-7500. doi: 10.18632/oncotarget.23556

Mitwasi N, Feldmann A, Bergmann R, Berndt N, Arndt C, Koristka S, et al. Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells. Oncotarget. 2017, 8(65):108584-108603. doi: 10.18632/oncotarget.21017

Pishali Bejestani E, Cartellieri M, Bergmann R, Ehninger A, Loff S, Kramer M, et al. Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model. Oncoimmunlogy. 2017, e1342909. doi: 10.1080/2162402X.2017.1342909. 

Albert S, Arndt C, Feldmann A, Bergmann R, Bachmann D, Koristka S, et al. A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform. Oncoimmunlogy. 2017, 6(4): e1287246. doi: 10.1080/2162402X.2017.1287246. 

Feldmann A, Arndt C, Bergmann R, Loff S, Cartellieri M, Bachmann D, et al. Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”.  Oncotarget. 2017, 8(19):31368-31385; doi: 10.18632/oncotarget.15572

Bachmann D, Aliperta R, Bergmann R et al. Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells. Oncotarget 2017. 9(7):7487-7500. doi: 10.18632/oncotarget.23556

Mitwasi N, Feldmann A, Bergmann R, Berndt N, Arndt C, Kosistka S, et a. Development of novel target modules for retargeting of UniCAR T cells to GD2-positive tumor cells. Oncotarget 2017; doi: 10.18632/oncotarget.21017. 

Dietrich J, Loff S, Meyer JE, von Bonin M, Hetzenecker M, Spehr J, et al. Targeting leukemia using an inducible universal chimeric antigen receptor (UniCAR) T cell technology. Cytotherapy 2017, 19(5), S9, Abstract.

Cartellieri M, Feldmann A, Koristka S, Arndt C, Loff S, Ehninger A, et al. Switching CAR T cells on and of: a novel modular platform for retargeting of T cells to AML blasts. Blood cancer J. 2016, 6(8):e458; doi: 10.1038/bcj.2016.61.

Loff S, von Bonin M, Dietrich J, Meyer JE, Feldmann A, Arndt C, et al. The UniCAR system: Inducible CAR T cells for precise reactivity and high efficacy against hematopoietic malignancies. Cancer Immunology Research. 2016, 4(11), DOI: 10.1158/2326-6066.IMM2016-B099, Abstract.

Cartellieri M, Loff S, von Bonin M, Bejestani EP, Ehninger E, Feldmann A, et al. UniCAR: A novel modular retargeting platform technology for CAR T cells. Blood 2015, 126: 5549, Abstract.

Cartellieri M, Koristka S, Arndt C, et al. A novel ex vivo isolation and expansion procedure for chimeric antigen receptor engrafted human T cells. PLoS One. 2014;9(4):e93745.

Koristka S, Cartellieri M, Feldmann A, Arndt C, Loff S, Michalk I, et al. Flexible antigen-specific redirection of human regulatory T cells via a novel universal chimeric antigen receptor system. Blood. 2014; 124:3494, Abstract.

Kloss CC, Condomines M, Cartellieri M, Bachmann M and Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 2013, 31:71-75.

Cartellieri M, Bachmann M, Feldmann A, et al. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol. 2010;2010:956304.

Morgenroth A, Cartellieri M, Schmitz M, et al. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate. 67:1121-1131.

Presentations at Scientific Meetings​

Dietrich et al. Abstract No. 2209 / 14 at AACR II Rapidly switchable universal CAR-T cells with improved safety profile allow for active targeting of PD-L1 expressing solid tumors. – PO.IM02.06 – Combination Immunotherapies 2, June 22, 2020, 9:00 AM – 6:00 PM (EDT).

Cartellieri et al. Abstract No. 2176 / 8 at AACR IIUsing a PSMA-specific low-molecular-weight compound for prostate cancer treatment with rapidly switchable universal CAR-T cells: Overcoming the challenges of cellular immunotherapies in solid tumors. – PO.IM02.02 – Adoptive Cell Therapy 2, June 22, 2020, 9:00 AM – 6:00 PM (EDT).

Loff et al. Abstract No. 4232 / 6 at AACR II More than a bridging therapy: Targeting CD123 with rapidly switchable universal CAR-T cells for treatment of acute leukemia. – PO.CL06.02 – Adoptive Cell Therapy 4 / Combination Immunotherapies, June 22, 2020, 9:00 AM – 6:00 PM (EDT).

Loff S, Meyer JE, Dietrich J, Spehr J, Julia R, von Bonin M, Gründer C, Franke K, Feldmann A, Bachmann M, Ehninger G, Ehninger A, Cartellieri M, 2018. Late-Stage Preclinical Characterization of Switchable CD123-Specific CAR-T for Treatment of Acute Leukemia. Blood 132, 964-964 (Abstract ASH 2018).

TCE Platform

Publications

Fasslrinner F, Arndt C, Koristka S, Feldmann A, Altmann H, von Bonin M, et al. Midostaurin abrogates CD33-directed UniCAR and CD33-CD3 bispecific antibody therapy in acute myeloid leukaemia. Br J Haematol. 2019, doi: 10.1111/bjh.15975.

Aliperta R, Welzel P, Bergmann R, Freudenberg U, Berndt N, Feldmann A, et al. Cryogel-supported stem cell factory for customized sustained release of bispecific antibodies for cancer immunotherapy. Scientific Reports. 2017, doi: 10.1038/srep42855

Ehninger A, Cartellieri M, Feldmann A, Arndt C, Koristka S, Loff S, et al. Improved killing of tumor cells by a novel flexible antibody-based modular T cell retargeting system. Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA, Abstract 2313 doi: 10.1158/1538-7445.AM2016-2313

Aliperta R, Cartellieri M, Feldmann A, Arndt C, Koristka S, Michalk I, et al. Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts. Blood Cancer Journal. 2015 5, e348; doi:10.1038/bcj.2015.73

Arndt C, Feldmann A, von Bonin M, et al. Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system. Leukemia. 2014;28(1):59-69.

Koristka S, Cartellieri M, Arndt C, Bippes CC, Feldmann A, Michalk I, et al. Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B. J Autoimmun. 2013, 42:105-116.

Arndt C, von Bonin M, Cartellieri M, et al. Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. Leukemia. 2013;27(4):964-967.

Stamova S, Feldmann A, Cartellieri M, et al. Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses. Anal Biochem. 2012;423(2):261-268.

Koristka S, Cartellieri M, Theil A, et al. Retargeting of human regulatory T cells by single-chain bispecific antibodies. J Immunol. 2012;188(3):1551-1558.

Feldmann A, Arndt C, Topfer K, et al. Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells. J Immunol. 2012;189(6):3249-3259.

Stamova S, Cartellieri M, Feldmann A, et al. Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells. Leukemia. 2011;25(6):1053-1056.

Stamova S, Cartellieri M, Feldmann A, et al. Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module. Mol Immunol. 2011;49(3):474-482

Feldmann A, Stamova S, Bippes CC, et al. Retargeting of T cells to prostate stem cell antigen expressing tumor cells: comparison of different antibody formats. Prostate. 2011;71(9):998-1011.

Andrew Schiermeier, Ph.D.

Chief Executive Officer

Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you.

Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you.